BRIEF-Rallybio Announces Positive Data For RLYB116 Phase 1 Study

Reuters

Yesterday

Feb 17 (Reuters) - Rallybio Corp RLYB.O:

RALLYBIO ANNOUNCES POSITIVE DATA FOR RLYB116 PHASE 1 STUDY DEMONSTRATING COMPLETE AND SUSTAINED INHIBITION OF TERMINAL COMPLEMENT
RALLYBIO CORP - RLYB116 PHASE 2 TRIAL PLANNED FOR 2H 2026 WITH POTENTIAL FOR TOPLINE DATA IN 2027
RALLYBIO CORP - RLYB116 DOSES WELL TOLERATED WITH NO GI SIDE EFFECTS

Source text: ID:nBw2q7DYLa

Further company coverage: RLYB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612574514"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612574514\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612574514?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 21:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612574514","market":"us","top_or_hot":-1,"title":"BRIEF-Rallybio Announces Positive Data For RLYB116 Phase 1 Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Rallybio Announces Positive Data For RLYB116 Phase 1 Study</title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span>Rallybio Corp <span>RLYB.O</span>:</p><ul><li><p>RALLYBIO ANNOUNCES POSITIVE DATA FOR RLYB116 PHASE 1 STUDY DEMONSTRATING COMPLETE AND SUSTAINED INHIBITION OF TERMINAL COMPLEMENT</p></li><li><p>RALLYBIO CORP - RLYB116 PHASE 2 TRIAL PLANNED FOR 2H 2026 WITH POTENTIAL FOR TOPLINE DATA IN 2027</p></li><li><p>RALLYBIO CORP - RLYB116 DOSES WELL TOLERATED WITH NO GI SIDE EFFECTS</p></li></ul><p>Source text: <span>ID:nBw2q7DYLa</span></p><p>Further company coverage: <span>RLYB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Rallybio Announces Positive Data For RLYB116 Phase 1 Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Rallybio Announces Positive Data For RLYB116 Phase 1 Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-17 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Rallybio Announces Positive Data For RLYB116 Phase 1 Study</title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span>Rallybio Corp <span>RLYB.O</span>:</p><ul><li><p>RALLYBIO ANNOUNCES POSITIVE DATA FOR RLYB116 PHASE 1 STUDY DEMONSTRATING COMPLETE AND SUSTAINED INHIBITION OF TERMINAL COMPLEMENT</p></li><li><p>RALLYBIO CORP - RLYB116 PHASE 2 TRIAL PLANNED FOR 2H 2026 WITH POTENTIAL FOR TOPLINE DATA IN 2027</p></li><li><p>RALLYBIO CORP - RLYB116 DOSES WELL TOLERATED WITH NO GI SIDE EFFECTS</p></li></ul><p>Source text: <span>ID:nBw2q7DYLa</span></p><p>Further company coverage: <span>RLYB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLYB","symbol_name":"Rallybio Corp.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA9LF1DQ:1","article_id":"2612574514","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612574514","pubTimestamp":1771335456,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Rallybio Announces Positive Data For RLYB116 Phase 1 StudyFeb 17 (Reuters) - Rallybio Corp RLYB.O:RALLYBIO ANNOUNCES POSITIVE DATA FOR RLYB116 PHASE 1 STUDY DEMONSTRATING COMPLETE AND SUSTAINED ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLYB":"Rallybio Corp.","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"简介-Rallybio宣布RLYB116 1期研究的积极数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLYB":0.9},"content_text":"BRIEF-Rallybio Announces Positive Data For RLYB116 Phase 1 StudyFeb 17 (Reuters) - Rallybio Corp RLYB.O:RALLYBIO ANNOUNCES POSITIVE DATA FOR RLYB116 PHASE 1 STUDY DEMONSTRATING COMPLETE AND SUSTAINED INHIBITION OF TERMINAL COMPLEMENTRALLYBIO CORP - RLYB116 PHASE 2 TRIAL PLANNED FOR 2H 2026 WITH POTENTIAL FOR TOPLINE DATA IN 2027RALLYBIO CORP - RLYB116 DOSES WELL TOLERATED WITH NO GI SIDE EFFECTSSource text: ID:nBw2q7DYLaFurther company coverage: RLYB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}